Background/Objectives: Claudin 18.2 (CLDN18.2) has emerged as a clinically actionable therapeutic target in gastrointestinal malignancies; however, its expression profile and prognostic significance in cholangiocarcinoma (CCA) remain incompletely characterized. This study investigated CLDN18.2 expression in CCA and eva...
T. Toyran, Kivilcim Eren Ates, F. Pi̇şki̇n et al.· Journal of Clinical Medicine· 0 citations
Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods:...
Mehmet Mutlu Kıdı, Mehmet Turker, Sedat Biter et al.· Cukurova Medical Journal· 0 citations
Background/Objectives: Immune checkpoint inhibitors have become a standard treatment option for advanced/metastatic non-small cell lung cancer (NSCLC); however, considerable heterogeneity exists among patients regarding treatment response and survival. This study aimed to determine whether the pretreatment modified Gla...
Sedat Biter, Mehmet Mutlu Kıdı, Yasemin Aydınalp Camadan et al.· Journal of Clinical Medicine· 0 citations
AbstractAim: Gastrointestinal stromal tumors (GISTs) exhibit marked heterogeneous clinical behavior that is not fully captured by conventional risk classification systems. This study aimed to evaluate the prognostic significance of loss of p16 expression and EZH2 overexpression and their relationship with clinicopathol...
T. Toyran, K. Ates, T. Köşeci et al.· Cukurova Anestezi ve Cerrahi...· 0 citations
Aim: Leptomeningeal metastasis (LM) from breast cancer carries a poor prognosis, and most published cohorts originate from high-volume referral centers. We aimed to identify factors associated with overall survival (OS) after an LM diagnosis in routine practice and to describe diagnostic and treatment patterns.Methods:...
Mehmet Mutlu Kıdı, Omer Kaya, Sedat Biter et al.· Cukurova Anestezi ve Cerrahi...· 0 citations
These exploratory findings do not support the clinical use of EZH2 as a biomarker at this stage; prospective, multicenter studies using predefined thresholds and standardized immunohistochemical methods are needed to clarify its potential role as a marker complementary to PD-L1.
E. Asarkaya, Hatice Asoğlu, Abdurrahman Aykut et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
